[
  {
    "qas": [
      {
        "answers": [
          {
            "text": "CONSULTING AGREEMENT",
            "answer_start": 135
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Document Name",
        "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Gianluca Rotino",
            "answer_start": 172
          },
          {
            "text": "Kiromic, Inc",
            "answer_start": 205
          },
          {
            "text": "Consultant",
            "answer_start": 360
          },
          {
            "text": "Company",
            "answer_start": 248
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Parties",
        "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "July 20, 2018",
            "answer_start": 157
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Agreement Date",
        "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "This letter agreement will be effective as of July 1, 2018.",
            "answer_start": 14454
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Effective Date",
        "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective\u00a0",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "This Agreement will commence on the Effective Date and will continue until termination as provided below.",
            "answer_start": 7676
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Expiration Date",
        "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Renewal Term",
        "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Notice Period To Terminate Renewal",
        "question": "Highlight the parts (if any) of this contract related to \"Notice Period To Terminate Renewal\" that should be reviewed by a lawyer. Details: What is the notice period required to terminate renewal?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "This Agreement shall be governed by the laws of the State of Texas, without reference to its conflicts of law principles.",
            "answer_start": 12387
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Governing Law",
        "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Most Favored Nation",
        "question": "Highlight the parts (if any) of this contract related to \"Most Favored Nation\" that should be reviewed by a lawyer. Details: Is there a clause that if a third party gets better terms on the licensing or sale of technology/goods/services described in the contract, the buyer of such technology/goods/services under the contract shall be entitled to those better terms?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Without limiting the foregoing, Consultant agrees to use his or her best efforts (A) to segregate Consultant's",
            "answer_start": 10361
          },
          {
            "text": "Consultant hereby certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, or that would preclude Consultant from complying with the provisions hereof, and further certifies that Consultant will not enter into any such conflicting agreement during the term of this Agreement.",
            "answer_start": 9648
          },
          {
            "text": "Subject to written waivers that may be provided by the Company upon request, which shall not be unreasonably withheld, Consultant agrees that, during the term of this Agreement, Consultant will not directly or indirectly (i) participate in the formation of any business or commercial entity in the Field of Interest or otherwise competitive with the Company.",
            "answer_start": 10002
          },
          {
            "text": "Services performed under this Agreement from Consultant's work done for any other companies for whom Consultant is providing services so as to minimize any questions of disclosure of, or rights under, any inventions, (B) to notify the Company if at any time the Consultant believes that such questions may result from his or her performance under this Agreement and (C) to assist the Company in fairly resolving any questions in this regard which may arise.",
            "answer_start": 10515
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Non-Compete",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?\u00a0",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Exclusivity",
        "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing\u00a0 commitment with the counterparty? This includes a commitment to procure all \u201crequirements\u201d from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on\u00a0 collaborating or working with other parties), whether during the contract or\u00a0 after the contract ends (or both).",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__No-Solicit Of Customers",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Customers\" that should be reviewed by a lawyer. Details: Is a party restricted from contracting or soliciting customers or partners of the counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Competitive Restriction Exception",
        "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__No-Solicit Of Employees",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party\u2019s soliciting or hiring employees and/or contractors from the\u00a0 counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Non-Disparagement",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Disparagement\" that should be reviewed by a lawyer. Details: Is there a requirement on a party not to disparage the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Either Consultant or Company may terminate this Agreement upon prior written notice thereof to the other party.",
            "answer_start": 7783
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Termination For Convenience",
        "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this\u00a0 contract without cause (solely by giving a notice and allowing a waiting\u00a0 period to expire)?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Rofr/Rofo/Rofn",
        "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Change Of Control",
        "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Consultant without the express written consent of Company.",
            "answer_start": 12107
          },
          {
            "text": "Consultant shall not subcontract any portion of Consultant's duties under this Agreement without the prior written consent of Company.",
            "answer_start": 11972
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Anti-Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Revenue/Profit Sharing",
        "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or\u00a0services?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Price Restrictions",
        "question": "Highlight the parts (if any) of this contract related to \"Price Restrictions\" that should be reviewed by a lawyer. Details: Is there a restriction on the\u00a0 ability of a party to raise or reduce prices of technology, goods, or\u00a0 services provided?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Minimum Commitment",
        "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "The Company will compensate Consultant at the rate of $400 per hour (19 hours cap monthly; anything over these hrs must be preapproved by management), payable in accordance with the Company's standard payroll schedule, and subject to withholding as legally required.",
            "answer_start": 17817
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Volume Restriction",
        "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one party\u2019s use of the product/services exceeds certain threshold?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Consultant hereby irrevocably assigns to Company all right, title and interest in and to any information (including, without limitation, business plans and/or business information), technology, know-how, materials, notes, records, designs, ideas, inventions, improvements, devices, developments, discoveries, compositions, trade secrets, processes, methods and/or techniques, whether or not patentable or copyrightable, that are conceived, reduced to practice or made by Consultant alone or jointly with others in the course of performing the Services or through the use of Confidential Information (collectively, 111nventions\").",
            "answer_start": 4293
          },
          {
            "text": "to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of such intellectual property rights thereon with the same legal force and effect as if executed by Consultant.",
            "answer_start": 6916
          },
          {
            "text": "Consultant agrees to sign, execute and acknowledge or cause to be signed, executed and acknowledged without cost, but at the expense of Company, any and all documents and to perform such acts as my be necessary, useful or convenient for the purposes of perfecting the foregoing assignments and obtaining, enforcing and defending intellectual property rights in any and all countries with respect to Inventions.",
            "answer_start": 4924
          },
          {
            "text": "Consultant agrees that if Company is unable because of Consultant's unavailability, mental or physical incapacity, or for any other reason, to secure Consultant's signature to apply for or to pursue any application or registration for any intellectual property rights covering any Invention, then Consultant hereby irrevocably designates and appoints Company and its duly authorized officers and agents as Consultant's agent and attorney-in-fact, to act for and in Consultant's behalf",
            "answer_start": 6388
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Ip Ownership Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created\u00a0 by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Joint Ip Ownership",
        "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention developed hereunder any invention, improvement, development concept, discovery or other proprietary subject matter owned by Consultant or in which Consultant has an interest (\"Item\"), Consultant will inform Company in writing thereof, and Company is hereby granted and shall have a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, reproduce, display, use and sell such Item as part of or in connection with the exploitation of such Invention.",
            "answer_start": 5782
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__License Grant",
        "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Non-Transferable License",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Affiliate License-Licensor",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?\u00a0",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Affiliate License-Licensee",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Unlimited/All-You-Can-Eat-License",
        "question": "Highlight the parts (if any) of this contract related to \"Unlimited/All-You-Can-Eat-License\" that should be reviewed by a lawyer. Details: Is there a clause granting one party an \u201centerprise,\u201d \u201call you can eat\u201d or unlimited usage license?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention developed hereunder any invention, improvement, development concept, discovery or other proprietary subject matter owned by Consultant or in which Consultant has an interest (\"Item\"), Consultant will inform Company in writing thereof, and Company is hereby granted and shall have a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, reproduce, display, use and sell such Item as part of or in connection with the exploitation of such Invention.",
            "answer_start": 5782
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Irrevocable Or Perpetual License",
        "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a\u00a0 license grant that is irrevocable or perpetual?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Source Code Escrow",
        "question": "Highlight the parts (if any) of this contract related to \"Source Code Escrow\" that should be reviewed by a lawyer. Details: Is one party required to deposit its source code into escrow with a third party, which can be released to the counterparty upon the occurrence of certain events (bankruptcy,\u00a0 insolvency, etc.)?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Upon the termination of this Agreement, or upon Company's earlier requests, Consultant will deliver to Company all property relating to, and all tangible embodiments of, Inventions in Consultant's possession or control.",
            "answer_start": 5561
          }
        ],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Post-Termination Services",
        "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Audit Rights",
        "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to\u00a0 audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Uncapped Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party\u2019s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Cap On Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party\u2019s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Liquidated Damages",
        "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Warranty Duration",
        "question": "Highlight the parts (if any) of this contract related to \"Warranty Duration\" that should be reviewed by a lawyer. Details: What is the duration of any\u00a0 warranty against defects or errors in technology, products, or services\u00a0 provided under the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Insurance",
        "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Covenant Not To Sue",
        "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty\u2019s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSULTING AGREEMENT__Third Party Beneficiary",
        "question": "Highlight the parts (if any) of this contract related to \"Third Party Beneficiary\" that should be reviewed by a lawyer. Details: Is there a non-contracting party who is a beneficiary to some or all of the clauses in the contract and therefore can enforce its rights against a contracting party?",
        "is_impossible": true
      }
    ],
    "context": "Exhibit 10.23 Corporate Address Fannin South Professional Building, Suite 140 7707 Fannin Street Houston, Texas 77054 t: 832.968.4888\n\nCONSULTING AGREEMENT\n\nJuly 20, 2018\n\nGianluca Rotino\n\nDear Gianluca:\n\nKiromic, Inc, a Delaware corporation (the \"Company\"), is pleased to this offer to this Consulting Agreement (this \"Agreement\") to retain Gianluca Rotino (\"Consultant\") to perform certain consulting activities as described below on the following terms:\n\n1. Services and Compensation. Consultant agrees to act as a consultant to Company with respect to such matters and projects as are mutually agreed from time to time by and between Consultant and Company, and perform the services described on Exhibit A hereto (collectively, \"Services\").\n\nCompany agrees to pay Consultant the compensation set forth on Exhibit A hereto for the performance of the Services.\n\n2. Confidentiality. \"Confidential Information\" means any proprietary information technical data, trade secrets or know-how, including, but not limited to, research and product plans, products, services, markets, developments, inventions, processes, formulas, technology, marketing, finances or other business information disclosed to Consultant by Company either directly or indirectly in writing, orally or otherwise. Confidential Information also includes all Inventions (as defined below) and any other information or materials generated in connection with the Services.\n\nConsultant shall not, during or subsequent to the term of this Agreement, use any Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of Company, or disclose Confidential Information to any third party. Consultant agrees that Confidential Information shall remain the sole property of Company. Consultant further agrees to take all reasonable precautions to prevent any unauthorized disclosure or use of Confidential Information. Notwithstanding the above, Consultant's obligation under this Section 2(b) relating to Confidential Information shall not apply to information which (i) is known to Consultant at the time of disclosure to Consultant by Company as evidenced by written records of Consultant, (ii) has become publicly known and made generally available through no wrongful act of Consultant, or (iii) has been rightfully received by Consultant from a third party authorized to make such disclosure.\n\nConsultant agrees that Consultant will not, during the term of this Agreement, improperly use or disclose to Company any proprietary information or trade secrets of any former or current employer or other person or entity to which Consultant has a duty to keep in confidence such information and that Consultant will not bring onto the premises of Company any unpublished document or proprietary information belonging to such employer, person or entity unless consented to in writing by the same. Consultant will indemnify Company and hold it harmless from 844.KEY.CURE | www.kiromic.com PAGE 1\n\n\n\n\n\nand against all claims, liabilities, damages and expenses, including reasonable attorneys' fees and costs of suit, arising out of or in connection with any violation or claimed violation by Company of such third party's rights resulting in whole or in part from Company's use of the work product of Consultant under this Agreement.\n\nConsultant recognizes that Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that Consultant owes Company and such third parties, during the term of this Agreement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out the Services for Company consistent with Company's agreement with such third party.\n\nUpon the termination of this Agreement, or upon Company's earlier request, Consultant will deliver to Company all Confidential Information and Company's property relating thereto and all tangible embodiments thereof, in Consultant's possession or control.\n\n3. Ownership. Consultant hereby irrevocably assigns to Company all right, title and interest in and to any information (including, without limitation, business plans and/or business information), technology, know-how, materials, notes, records, designs, ideas, inventions, improvements, devices, developments, discoveries, compositions, trade secrets, processes, methods and/or techniques, whether or not patentable or copyrightable, that are conceived, reduced to practice or made by Consultant alone or jointly with others in the course of performing the Services or through the use of Confidential Information (collectively, 111nventions\").\n\nConsultant agrees to sign, execute and acknowledge or cause to be signed, executed and acknowledged without cost, but at the expense of Company, any and all documents and to perform such acts as my be necessary, useful or convenient for the purposes of perfecting the foregoing assignments and obtaining, enforcing and defending intellectual property rights in any and all countries with respect to Inventions. It is understood and agreed that Company or Company's designee shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain patent applications and patents worldwide with respect to Inventions.\n\nUpon the termination of this Agreement, or upon Company's earlier requests, Consultant will deliver to Company all property relating to, and all tangible embodiments of, Inventions in Consultant's possession or control.\n\nConsultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention developed hereunder any invention, improvement, development concept, discovery or other proprietary subject matter owned by Consultant or in which Consultant has an interest (\"Item\"), Consultant will inform Company in writing thereof, and Company is hereby granted and shall have a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, reproduce, display, use and sell such Item as part of or in connection with the exploitation of such Invention.\n\nConsultant agrees that if Company is unable because of Consultant's unavailability, mental or physical incapacity, or for any other reason, to secure Consultant's signature to apply for or to pursue any application or registration for any intellectual property rights covering any Invention, then Consultant hereby irrevocably designates and appoints Company and its duly authorized officers and agents as Consultant's agent and attorney-in-fact, to act for and in Consultant's behalf 844.KEY.CURE | www.kiromic.com PAGE 2\n\n\n\n\n\nto execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of such intellectual property rights thereon with the same legal force and effect as if executed by Consultant.\n\n4. Reports. Consultant agrees, from time to time during the term of this Agreement, to keep Company advised as to Consultant's progress in performing the Services and, as reasonably requested by Company, prepare written reports with respect thereto. It is understood that the time required in the preparation of such written reports shall be considered time devoted to the performance of the Services by Consultant. All such reports prepared by Consultant shall be the sole property of Company.\n\n5. Term and Termination. This Agreement will commence on the Effective Date and will continue until termination as provided below.\n\nEither Consultant or Company may terminate this Agreement upon prior written notice thereof to the other party.\n\nUpon termination of this Agreement, all rights and duties of the parties hereunder shall cease except:\n\nCompany shall be obliged to pay, within thirty (30) days after receipt of Consultant's final statement, all amounts owing to Consultant for unpaid Services completed by Consultant and related expenses, if any, in accordance with the provisions of Section 1 hereof, and Sections 2, 3, S(c), 6, 7, 8 and 10 shall survive termination of this Agreement.\n\n6. Independent Contractor. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent, employee or representative of Company, but Consultant shall perform the Services as an independent contractor. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement.\n\n7. No Debarment. Consultant represents and warrants that Consultant has not been debarred under Section (a) or (b) of 21 U.S.C. Section 335a and does not appear on the United States Food and Drug debarment list. Consultant represents and warrants that Consultant has not committed any crime or conduct that could result in such debarment or Consultant's exclusion from any governmental healthcare program. Consultant represents and warrants that, to Consultant's knowledge, no investigations, claims or proceedings with respect to any such crimes or conduct are pending or threatened against Consultant. Consultant agrees and undertakes to promptly notify the Company if Consultant becomes debarred or proceedings have been initiated against Consultant with respect to debarment, whether such debarment or initiation of proceedings occurs during or after the term of this Agreement.\n\n8. Conflicting Obligations. Consultant hereby certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, or that would preclude Consultant from complying with the provisions hereof, and further certifies that Consultant will not enter into any such conflicting agreement during the term of this Agreement. Subject to written waivers that may be provided by the Company upon request, which shall not be unreasonably withheld, Consultant agrees that, during the term of this Agreement, Consultant will not directly or indirectly (i) participate in the formation of any business or commercial entity in the Field of Interest or otherwise competitive with the Company. Without limiting the foregoing, Consultant agrees to use his or her best efforts (A) to segregate Consultant's 844.KEY.CURE | www.kiromic.com PAGE 3\n\n\n\n\n\nServices performed under this Agreement from Consultant's work done for any other companies for whom Consultant is providing services so as to minimize any questions of disclosure of, or rights under, any inventions, (B) to notify the Company if at any time the Consultant believes that such questions may result from his or her performance under this Agreement and (C) to assist the Company in fairly resolving any questions in this regard which may arise. The Services performed hereunder will not be conducted on time that is required to be devoted to any other third party. The Consultant shall not use the funding, resources and facilities of any other third party, without the prior written consent of the Company, to perform Services hereunder and shall not perform the Services hereunder in any manner that would give any third-party rights or access to the product of such Services.\n\n9. General. This Agreement (together with the Exhibits hereto) is the sole agreement and understanding between Company and Consultant concerning the subject matter hereof, and it supersedes any and all prior agreements and understandings with respect to such matter, whether written or oral, provided, that, except as set forth in Exhibit B. Any required notice shall be given in writing by customary means with receipt confirmed at the address of each party set forth below, or to such other address as either party may substitute by written notice to the other. Consultant shall not subcontract any portion of Consultant's duties under this Agreement without the prior written consent of Company. Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Consultant without the express written consent of Company. Company may assign this Agreement to any entity that succeeds to substantially all of the business or assets of Company. This Agreement shall be governed by the laws of the State of Texas, without reference to its conflicts of law principles. This Agreement may only be amended or modified by a writing signed by both parties. Waiver of any term or provision of this Agreement or forbearance to enforce any term or provision by either party shall not constitute a waiver as to any subsequent breach or failure of the same term or provision or a waiver of any other term or provision of this Agreement. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision, provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to either Company or Consultant.\n\n10. Tax Matters. As follows:\n\n(a) Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.\n\n(b) Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.\n\n11. Background Check and Authorization to Work. This offer of employment is contingent on the Company's completion of a satisfactory background check of you. Please note that because of employer regulations adopted in the Immigration Reform and Control Act of 1986, within three (3) business days of starting your new position you will need to present documentation demonstrating that you have authorization to work in the United States. If you have questions about this requirement, which applies to U.S. citizens and non-U.S. citizens alike, please let us know.\n\n12. Interpretation, Amendment and Enforcement. This letter agreement will be effective as of July 1, 2018. This letter agreement and the Company's standard Proprietary Information and Inventions Agreement supersede and replace any prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and 844.KEY.CURE | www.kiromic.com PAGE 4\n\n\n\n\n\nthe Company and constitute the complete agreement between you and the Company regarding the subject matter set forth herein. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.\n\n13. Arbitration Agreement. Any controversy or claim arising out of or relating to this agreement or breach thereof, shall be settled by binding arbitration controlled by the rules of the American Arbitration Association. The number of arbitrator(s) shall be one. The seat of arbitration shall be Houston, Texas. Texas law shall also apply to the extent necessary to fill any gaps created by the rules of the American Arbitration Association. The arbitration award shall be final and binding on the parties. Judgement of the award rendered by the arbitrator(s) may be entered into any court of competent jurisdiction. If any provision of this Arbitration Agreement is held illegal or unenforceable in a arbitration proceeding, such provision shall be severed and shall be inoperative, and the remainder of this Agreement shall remain operative and binding on the Parties. The arbitrator(s) shall have sole kompetenz-kompetenz regarding this Arbitration Agreement.\n\n14. Severability. If any provision of this Agreement is held illegal or unenforceable in a judicial proceeding, such provision shall be severed and shall be inoperative, and the remainder of this Agreement shall remain operative and binding on the Parties.\n\n15. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together will constitute one and the same agreement.\n\n16. Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between the parties hereto with respect to such subject matter.\n\n[SIGNATURE PAGE TO FOLLOW] 844.KEY.CURE | www.kiromic.com PAGE 5\n\n\n\n\n\nIN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date. KIROMIC, INC: CONSULTANT:\n\nBy: /s/ Scott Dahlbeck /s/ Gianluca Rotino Signature\n\nName: Scott Dahlbeck Gianluca Rotino\n\nTitle: President 844.KEY.CURE | www.kiromic.com PAGE 6\n\n\n\n\n\nEXHIBIT A\n\nSERVICES AND COMPENSATION\n\n1. Services. Consultant will render to Company the following Services: \u2022 Provide business and statistical analysis of company metrics \u2022 Provide leadership role for business development strategies \u2022 Manage all in house consulting duties to maximize return for company objectives \u2022 Manage key marketing and communication campaigns \u2022 Prioritize and support clinical product pipeline business priorities \u2022 Work closely with executive team to ensure department initiatives are all aligned \u2022 Locate, evaluate and develop new business contacts and opportunities\n\n2. Compensation. The Company will compensate Consultant at the rate of $400 per hour (19 hours cap monthly; anything over these hrs must be preapproved by management), payable in accordance with the Company's standard payroll schedule, and subject to withholding as legally required. This compensation will be subject to adjustment pursuant to the Company's consultant compensation policies in effect from time to time. Consultants shall be given written notice of any adjustments to compensation at least fourteen (14) days prior to adjustments becoming effective. 844.KEY.CURE | www.kiromic.com PAGE 7"
  }
]